Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases, today ...

(RTTNews) - Viridian Therapeutics (VRDN) Monday has granted 113,200 stock options to nine new employees and 310,700 stock options to newly appointed Chief Medical Officer, Dr. Radhika Tripuraneni.

Viridian Therapeutics (NASDAQ:VRDN) shares shot up 25% in early trading Monday after the company reported positive topline results from a Phase 3 study of its drug veligrotug in the treatment of ...

Investment analysts at B. Riley issued their Q1 2025 earnings per share estimates for Viridian Therapeutics in a research ...

Viridian Therapeutics' VRDN-001 demonstrates rapid efficacy in TED. Read why VRDN stock may benefit from FDA approval and ...

Viridian designed VRDN-003 to be an infrequent, at-home, and self-administered subcutaneous injection using a low-volume autoinjector. REVEAL-1 and REVEAL-2 Progressing as Planned: Patient ...

We refer to a media article on 13 March where, in summary, Crescent Capital Partners states a continuing interest in pursuing its conditional proposal as announced in December 2024 and an intention to ...

CNW/ - Viridian Metals Inc. (CSE: VRDN) ( "Viridian") is pleased to announce the final results from its 2024 man-portable ...

Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for serious and rare diseases ...

--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare ...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing ...